このページの翻訳は実験的なもので、現在開発中です。お待ちしております
GlaxoSmithKline Pharmaceuticals 過去の業績
過去 基準チェック /36
GlaxoSmithKline Pharmaceuticalsは、平均年間13.7%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間17% 1.4%収益成長率で 成長しています。 GlaxoSmithKline Pharmaceuticalsの自己資本利益率は33.2%であり、純利益率は17.1%です。
主要情報
16.7%
収益成長率
16.6%
EPS成長率
Pharmaceuticals 業界の成長 | 17.5% |
収益成長率 | 1.6% |
株主資本利益率 | 36.0% |
ネット・マージン | 18.3% |
次回の業績アップデート | 29 Oct 2024 |
最近の業績更新
Recent updates
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease
Aug 29The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 05Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%
Jun 01With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case
May 05GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear
Apr 14Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Feb 15Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?
Jan 18GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected
Dec 28Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today
Oct 05Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?
Sep 12GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet
Mar 17Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?
Sep 02GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly
Mar 02The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On
Mar 20Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?
Feb 27Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?
Feb 06What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?
Jan 11GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain
Dec 06Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts
Nov 01Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield
Oct 29What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?
Sep 29If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today
Aug 30Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?
Aug 02It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend
Jul 12Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?
Jul 07収支内訳
収支内訳
GlaxoSmithKline Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Jun 24 | 35,067 | 6,400 | 7,220 | 0 |
31 Mar 24 | 34,537 | 5,900 | 7,358 | 0 |
31 Dec 23 | 33,114 | 5,289 | 7,116 | 0 |
30 Sep 23 | 33,084 | 6,478 | 7,233 | 0 |
30 Jun 23 | 32,683 | 6,237 | 7,200 | 0 |
31 Mar 23 | 32,517 | 6,076 | 7,062 | 0 |
31 Dec 22 | 32,739 | 4,195 | 7,163 | 0 |
30 Sep 22 | 32,875 | 3,940 | 7,057 | 0 |
30 Jun 22 | 33,048 | 3,897 | 7,238 | 0 |
31 Mar 22 | 32,780 | 3,808 | 7,397 | 0 |
31 Dec 21 | 34,861 | 5,100 | 7,521 | 0 |
30 Sep 21 | 34,708 | 4,962 | 7,689 | 0 |
30 Jun 21 | 33,403 | 3,684 | 7,629 | 0 |
31 Mar 21 | 29,256 | 2,873 | 6,858 | 0 |
31 Dec 20 | 31,609 | 4,819 | 7,523 | 0 |
30 Sep 20 | 30,823 | -3,358 | 7,598 | 0 |
30 Jun 20 | 30,850 | 905 | 7,533 | 0 |
31 Mar 20 | 32,244 | 932 | 7,741 | 0 |
31 Dec 19 | 31,994 | 1,019 | 7,579 | 0 |
30 Sep 19 | 32,461 | 8,768 | 7,168 | 0 |
30 Jun 19 | 31,804 | 4,749 | 7,088 | 0 |
31 Mar 19 | 31,281 | 4,454 | 6,925 | 0 |
31 Mar 18 | 28,715 | 3,507 | 6,402 | 0 |
31 Mar 17 | 29,085 | 3,368 | 6,029 | 0 |
31 Mar 16 | 28,379 | 3,761 | 5,601 | 0 |
31 Mar 15 | 26,384 | 3,811 | 5,235 | 0 |
31 Dec 13 | 25,597 | 4,817 | 6,605 | 0 |
質の高い収益: GLAXOは 高品質の収益 を持っています。
利益率の向上: GLAXOの現在の純利益率 (17.1%)は、昨年(18.7%)よりも低くなっています。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: GLAXOの収益は過去 5 年間で年間13.7%増加しました。
成長の加速: GLAXOの過去 1 年間の収益成長率 ( 2.6% ) は、5 年間の平均 ( 年間16.7%を下回っています。
収益対業界: GLAXOの過去 1 年間の収益成長率 ( 2.6% ) Pharmaceuticals業界18.4%を上回りませんでした。
株主資本利益率
高いROE: GLAXOの 自己資本利益率 ( 33.2% ) は 高い とみなされます。